http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전해도금 공정온도가 Co-Pt 합금 박막의 미세구조 및 자기적 특성에 미치는 영향
이창형,정근희,박정갑,이광근,서수정,Lee, C.H.,Jeong, G.H.,Park, J.K.,Lee, K.K.,Suh, S.J. 한국결정성장학회 2008 한국결정성장학회지 Vol.18 No.2
Co-Pt 합금 박막은 amino-citrate 기반의 전해액에서 Ru(30 nm)/Ta(5 nm)/Si(100)구조의 작업 전극을 사용하여 정전류 전해도금 방법으로 증착 하였다. (0002) 우선 성장된 Ru의 buffer layers를 사용하여 Co-Pt 합금 박막의 결정구조와 우선 성장을 조절하였다. 본 실험에서는 도금액 온도를 변화시킴에 따른 Co-Pt 합금 박막의 자기적 성질과 미세구조에 미치는 영향을 고찰하였다. Co-Pt 합금 박막의 형상과 조성은 FESEM 과 EDS로 확인하였고, XRD로 결정구조를 분석하였다. 자기적 성질은 진동 시료 자력계와 토오크 자력계로 분석하였다. Co-Pt 합금 박막은 박막표면과 수직한 방향에서 열처리 없이 각각 6527 Oe의 높은 보자력과 0.93의 높은 각형비를 나타내었다. Co-Pt alloy thin films were galvanostatically electrodeposited on Ru (30 nm)/Ta (5 nm)/Si (100) substrates from a amino-citrate based electrolyte. We used Ru(0002)-oriented buffer layers to control the crystallinity and orientation of the Co-Pt alloy thin films. The effect of solution temperature on the microstructure and magnetic properties of the Co-Pt alloy thin film was investigated. The samples were characterized by EDS, FESEM, XRD diffractometer using Cu $K{\alpha}$ radiation. The magnetic properties of these films were analyzed by a VSM and torque magnetometer. The Co-Pt alloy thin films were exhibited very high out-of-plane coercivity and squareness of the multilayer were 6527 Oe and 0.93, respectively, without heat treatment.
이창형 대한간학회 2010 Clinical and Molecular Hepatology(대한간학회지) Vol.16 No.4(S)
Hepatitis C virus (HCV) causes significant morbidity and mortality worldwide with nearly 3% of the world population infected by this virus. Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. HCV is currently treated with pegylated interferon-a (peg-IFN-a) and ribavirin for 24~72 weeks. Unfortunately, these limited treatment options often produce significant side effects, resulting in complete viral eradication in 40~80% of patients. Therefore, the need for improvement of existing therapies and for development of new effective, safe and tolerable drugs is a matter of great clinical relevance and importance. Numerous directly-acting anti-viral agents are currently under clinical phase I-III evaluation. Significant progress has been made in the field of STAT-C drug development. These new antiviral agents are expected to improve treatment significantly with potentially shorter treatment duration. But, resistance development and safety of STAT-C compounds will play a key role in the quest for optimal hepatitis C treatment. STAT-C compounds in addition to pegylated interferon-alfa and ribavirin can improve SVR rates at least in HCV genotype 1 patients. Despite the well-known side-effects, peg-IFN with ribavirin will remain the backbone of hepatitis C treatment in the near future.